Innoviva, Inc. (INVA): Business Model Canvas [11-2024 Updated]
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Innoviva, Inc. (INVA) Bundle
Innoviva, Inc. (INVA) stands at the forefront of pharmaceutical innovation, focusing on respiratory and infectious diseases. By leveraging strategic partnerships and a robust product portfolio, Innoviva is committed to enhancing patient outcomes while navigating a complex healthcare landscape. Discover how their business model canvas reveals the intricate strategies that drive their success and value creation in the pharmaceutical sector.
Innoviva, Inc. (INVA) - Business Model: Key Partnerships
Collaborates with Glaxo Group Limited (GSK)
Innoviva has a significant collaboration with Glaxo Group Limited (GSK) focused on respiratory products. Under the collaboration agreement, Innoviva receives royalties from GSK on the sales of various products including:
| Product | Royalties (3 Months Ended September 30, 2024) | Royalties (3 Months Ended September 30, 2023) | Change |
|---|---|---|---|
| RELVAR/BREO | $48,199,000 | $45,585,000 | $2,614,000 (6%) |
| ANORO | $12,313,000 | $11,429,000 | $884,000 (8%) |
| Total Royalties | $60,512,000 | $57,014,000 | $3,498,000 (6%) |
For the nine months ended September 30, 2024, total net royalty revenue from GSK was $189,581,000, an increase from $183,049,000 in the same period of 2023.
Partnerships with Research Institutions like George Washington University
Innoviva collaborates with various research institutions, including George Washington University. These partnerships are vital for advancing research and development initiatives, particularly in the field of infectious diseases and new therapeutic agents.
Engages with Third-Party Manufacturers for Drug Production
Innoviva has established relationships with third-party manufacturers to ensure the production of its pharmaceutical products. Notably, the company has a Commercial Supply Agreement with Corden Pharma CHENÔVE SAS, which involves:
- Commitments for minimum purchases through December 31, 2027.
- Outstanding purchase commitments totaling approximately $30.4 million for the years 2024 to 2027.
Collaborates with Global Antibiotic Research and Development Partnership (GARDP)
Innoviva is actively engaged with the Global Antibiotic Research and Development Partnership (GARDP) to develop zoliflodacin, an investigational oral antibiotic. This collaboration focuses on:
- Clinical development for the treatment of uncomplicated gonorrhea.
- Presentations of findings at significant conferences such as the 2024 Sexually Transmitted Infections Prevention Conference.
Innoviva, Inc. (INVA) - Business Model: Key Activities
Research and development of pharmaceutical products
Innoviva, Inc. is heavily invested in the research and development (R&D) of pharmaceutical products. As of September 30, 2024, the company reported R&D expenses of $9.99 million for the nine-month period, compared to $31.57 million in the same period of 2023. This decline reflects a strategic focus on optimizing their R&D investments while continuing to develop key product candidates, such as XACDURO® and zoliflodacin.
Marketing and sales of marketed drugs
In the third quarter of 2024, Innoviva generated net product sales of $27.82 million, a significant increase from $13.70 million in the same quarter of 2023. The sales breakdown includes:
- GIAPREZA®: $13.80 million
- XERAVA®: $4.20 million
- XACDURO®: $9.80 million
This sales growth is attributed to enhanced marketing efforts and a stronger sales force, with approximately 71% of sales coming from U.S. customers.
Management of royalty agreements
Innoviva's royalty revenue for the third quarter of 2024 amounted to $60.51 million, up from $57.01 million in the previous year. Notable contributions to this revenue include:
- Royalties from RELVAR/BREO®: $48.20 million
- Royalties from ANORO®: $12.31 million
The total net royalty revenue for the nine months ended September 30, 2024, was $179.21 million, indicating a continued solid performance from these products.
Strategic acquisitions to expand product portfolio
In 2024, Innoviva completed several strategic acquisitions, including Entasis and La Jolla, aimed at enhancing its product portfolio in the infectious disease and hospital settings. The acquisition of Entasis alone contributed $106.7 million in intangible assets, primarily for its in-process research and development.
As of September 30, 2024, the company holds total assets of $1.23 billion, with cash and cash equivalents reported at $260.63 million.
| Key Activity | Financial Metric | Amount (in millions) | Period |
|---|---|---|---|
| R&D Expenses | Total Expenses | $9.99 | Q3 2024 |
| Net Product Sales | Total Sales | $27.82 | Q3 2024 |
| Royalty Revenue | Total Royalty Revenue | $60.51 | Q3 2024 |
| Intangible Assets from Acquisitions | Intangible Assets | $106.7 | 2024 |
| Cash and Cash Equivalents | Total Assets | $260.63 | Q3 2024 |
Innoviva, Inc. (INVA) - Business Model: Key Resources
Strong portfolio of respiratory and infectious disease assets
Innoviva has established a robust portfolio in the respiratory and infectious disease sectors, significantly contributing to its revenue streams. For the three months ended September 30, 2024, Innoviva reported net product sales of $27.8 million, with key contributions from GIAPREZA® ($13.8 million), XERAVA® ($4.2 million), and XACDURO® ($9.8 million). Over the nine months ended September 30, 2024, total net product sales reached $68.6 million.
Intellectual property rights for key products
Innoviva's intellectual property portfolio includes patents and collaboration agreements essential for its product pipeline. The company recognized a total net royalty revenue of $57.1 million for the three months ended September 30, 2024, an increase from $53.6 million in the same period of 2023. This includes royalties from significant products like RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which are pivotal to Innoviva's revenue generation strategy.
Experienced management team
Innoviva's management team comprises seasoned professionals with extensive experience in the pharmaceutical and biotechnology industries. This expertise is pivotal in navigating the complex landscape of drug development, regulatory compliance, and market entry strategies. As of September 30, 2024, the company had 22,216 outstanding options and awards under its equity incentive plan, reflecting a commitment to attracting and retaining top talent.
Financial resources including cash and investments
As of September 30, 2024, Innoviva reported total stockholders' equity of $668.5 million. The company generated $129.5 million in net cash from operating activities during the nine months ended September 30, 2024. Additionally, Innoviva's investment portfolio includes significant holdings in Armata Pharmaceuticals, valued at approximately $59.4 million as of September 30, 2024. This positions Innoviva to leverage its financial resources for further development and strategic acquisitions in the healthcare sector.
| Financial Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Product Sales | $27.8 million | $13.7 million | $68.6 million | $40.9 million |
| Net Royalty Revenue | $57.1 million | $53.6 million | $179.2 million | $172.7 million |
| Total Stockholders' Equity | $668.5 million | - | - | - |
| Net Cash from Operating Activities | $129.5 million | $107.8 million | - | - |
| Value of Armata Holdings | $59.4 million | - | - | - |
Innoviva, Inc. (INVA) - Business Model: Value Propositions
Innovative treatments for respiratory and infectious diseases
Innoviva, Inc. focuses on developing innovative treatments for respiratory and infectious diseases. Their flagship products include GIAPREZA®, XERAVA®, and XACDURO®. For the nine months ended September 30, 2024, net product sales for these products were $68.6 million, with individual contributions of $39.0 million from GIAPREZA®, $15.2 million from XERAVA®, and $14.4 million from XACDURO®.
Reliable revenue stream from royalty agreements
Innoviva generates a significant portion of its revenue through royalty agreements. For the third quarter of 2024, total net royalty revenue reached $57.1 million, an increase from $53.6 million in the same quarter of 2023. The total net royalty revenue for the nine months ended September 30, 2024, was $179.2 million, compared to $172.7 million in 2023. This revenue stream primarily comes from partnerships with GSK for products like RELVAR®/BREO® and ANORO®.
Commitment to improving patient health outcomes
Innoviva is dedicated to improving patient health outcomes through its innovative therapies. The company has established a robust pipeline, including XACDURO®, which targets hospital-acquired bacterial pneumonia and has been nominated for the 2024 Prix Galien USA Award for Best Biotechnology Product. Their ongoing research and development efforts reflect a commitment to addressing critical health challenges in respiratory and infectious diseases.
Diversified product offerings targeting critical care
Innoviva's product portfolio is diversified, targeting critical care and infectious diseases. In addition to GIAPREZA®, XERAVA®, and XACDURO®, the company is developing zoliflodacin, a potential first-in-class oral antibiotic for uncomplicated gonorrhea. The company's strategic acquisitions, such as Entasis and La Jolla, have further enhanced its capabilities in the infectious disease space.
| Product | Net Sales Q3 2024 (in millions) | Net Sales Q3 2023 (in millions) | Net Sales 9M 2024 (in millions) | Net Sales 9M 2023 (in millions) |
|---|---|---|---|---|
| GIAPREZA® | 13.8 | 8.0 | 39.0 | 28.2 |
| XERAVA® | 4.2 | 5.1 | 15.2 | 12.1 |
| XACDURO® | 9.8 | 0.6 | 14.4 | 0.6 |
| Total | 27.8 | 13.7 | 68.6 | 40.9 |
As of September 30, 2024, Innoviva's total assets were valued at $1.23 billion, with total liabilities of $562 million. The company's strategic focus on innovative treatments, reliable revenue from royalties, and diversified offerings positions it well to address critical healthcare needs in its target markets.
Innoviva, Inc. (INVA) - Business Model: Customer Relationships
Direct engagement with healthcare providers
Innoviva, Inc. maintains a direct engagement with healthcare providers, primarily focusing on hospitals and specialty clinics. Their approach includes providing personalized support and education regarding their products, particularly in critical care settings. For the three months ended September 30, 2024, Innoviva reported net product sales of $27.8 million, demonstrating a significant engagement level with healthcare providers.
Support through specialty distributors
Innoviva utilizes specialty distributors to enhance access to their critical care products. This strategy ensures that healthcare providers have timely access to necessary medications. The net product sales for the nine months ended September 30, 2024, totaled $68.6 million, with approximately 71% of these sales derived from U.S. customers, which indicates a strong reliance on specialty distributors for market penetration.
Focus on maintaining strong ties with GSK and other partners
Innoviva places a strong emphasis on maintaining robust relationships with strategic partners such as GlaxoSmithKline (GSK). In the third quarter of 2024, Innoviva recognized royalty revenue from GSK amounting to $60.5 million, up from $57.0 million in the same quarter of 2023. This revenue stream is critical for Innoviva's business model, as it not only provides financial support but also strengthens collaboration on product development and marketing.
Active communication regarding product updates and clinical data
Innoviva actively communicates with its healthcare partners regarding product updates and clinical data. They presented findings on their investigational agent zoliflodacin at significant conferences, showcasing their commitment to sharing valuable clinical information with stakeholders. For instance, data presented at the 2024 Sexually Transmitted Infections Prevention Conference highlighted the efficacy of zoliflodacin, reinforcing their engagement strategy through transparency and education.
| Type of Engagement | Details | Financial Impact (Q3 2024) |
|---|---|---|
| Direct Engagement with Healthcare Providers | Personalized support and education in critical care settings. | $27.8 million in net product sales |
| Specialty Distributors | Ensures timely access to medications for healthcare providers. | $68.6 million total net product sales (71% from U.S. customers) |
| Partnerships with GSK | Collaboration on product development and marketing. | $60.5 million in royalty revenue |
| Communication of Clinical Data | Active presentations of clinical findings to healthcare partners. | Enhanced stakeholder engagement and product credibility |
Innoviva, Inc. (INVA) - Business Model: Channels
Specialty distributors for product sales
Innoviva, Inc. utilizes specialty distributors to facilitate the sales of its pharmaceutical products. For the three months ended September 30, 2024, net product sales amounted to $27.8 million, with GIAPREZA® contributing $13.8 million, XERAVA® $4.2 million, and XACDURO® $9.8 million. Approximately 71% of these sales were derived from U.S. customers.
Direct sales teams for hospital engagement
The company employs direct sales teams that focus on engaging hospitals and healthcare providers. This strategy has proven effective, as evidenced by a substantial increase in U.S. net product sales from $19.7 million in Q3 2024, up from $11.8 million in Q3 2023. The direct engagement approach is critical for promoting products like XACDURO®, which targets specific hospital-acquired infections.
Online platforms for information dissemination
Innoviva leverages online platforms to disseminate information about its products, including clinical data, usage guidelines, and patient education. The company reported total revenue of $89.5 million for the third quarter of 2024, which includes net product sales and licenses. This digital outreach complements traditional sales methods by providing healthcare professionals with easy access to important product information.
Collaborations with healthcare institutions for product trials
Collaborative efforts with healthcare institutions are a cornerstone of Innoviva's strategy for product trials. Through partnerships, Innoviva can conduct clinical trials to validate the efficacy of its products, which subsequently supports its marketing efforts. For instance, the collaboration with Zai Lab for the development and commercialization of products in the Asia-Pacific region includes significant research and development support payments, potentially amounting to $91 million.
| Channel | Description | Financial Impact (Q3 2024) |
|---|---|---|
| Specialty Distributors | Facilitates sales of pharmaceuticals through specialized channels | $27.8 million in net product sales |
| Direct Sales Teams | Engagement with hospitals for product promotion | $19.7 million U.S. net product sales |
| Online Platforms | Information dissemination and patient education | Part of $89.5 million total revenue |
| Collaborations | Partnerships for clinical trials and product development | Up to $91 million in potential R&D support |
Innoviva, Inc. (INVA) - Business Model: Customer Segments
Hospitals and healthcare systems
Innoviva, Inc. serves hospitals and healthcare systems primarily through its critical care products. For the nine months ended September 30, 2024, net product sales to hospitals contributed significantly, with total net product sales reaching $68.6 million. Notably, GIAPREZA® accounted for $39 million of these sales, demonstrating its critical role in hospital settings.
Specialty pharmacies
Specialty pharmacies play a crucial role in distributing Innoviva's products. The company reported that approximately 71% of its net product sales during the third quarter of 2024 came from customers located in the U.S., including specialty pharmacies. The strategic partnerships with these pharmacies enhance access to Innoviva's critical care medications, specifically GIAPREZA®, XERAVA®, and XACDURO®, which collectively generated $27.8 million in net product sales for the three months ended September 30, 2024.
Physicians and healthcare professionals
Innoviva targets physicians and healthcare professionals as key customer segments, focusing on those involved in critical care and infectious disease management. The company’s sales efforts are aimed at educating healthcare providers about the benefits of its products. For example, during the nine months ended September 30, 2024, the net sales from GIAPREZA®, XERAVA®, and XACDURO® were $68.6 million, indicating the effectiveness of their outreach to healthcare professionals.
Patients requiring critical care medications
Patients requiring critical care medications are central to Innoviva's customer segments. The company’s products, such as GIAPREZA® and XACDURO®, are designed to address severe medical conditions. The sales data reflects a robust demand, with net product sales for GIAPREZA® alone reaching $39 million in the nine months ended September 30, 2024. This highlights the importance of Innoviva's offerings in treating patients with critical health needs.
| Customer Segment | Net Product Sales (Q3 2024) | Net Product Sales (9M 2024) | Key Products |
|---|---|---|---|
| Hospitals and Healthcare Systems | $27.8 million | $68.6 million | GIAPREZA®, XERAVA®, XACDURO® |
| Specialty Pharmacies | Not specifically listed | Approximately 71% of U.S. sales | GIAPREZA®, XERAVA®, XACDURO® |
| Physicians and Healthcare Professionals | Not specifically listed | Part of $68.6 million | GIAPREZA®, XERAVA®, XACDURO® |
| Patients Requiring Critical Care Medications | Not specifically listed | Part of $68.6 million | GIAPREZA®, XACDURO® |
Innoviva, Inc. (INVA) - Business Model: Cost Structure
Research and Development Expenses
Research and development expenses for Innoviva, Inc. for the three months ended September 30, 2024, were $3.6 million, compared to $4.0 million for the same period in 2023. For the nine months ended September 30, 2024, these expenses totaled $10.0 million, a significant decrease from $31.6 million in 2023, representing a decline of approximately 68%.
Breakdown of research and development expenses for the three and nine months ended September 30, 2024, compared to 2023, is as follows:
| Expense Type | Three Months Ended September 30, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Nine Months Ended September 30, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) |
|---|---|---|---|---|
| Compensation and Related Personnel Costs | $978 | $1,825 | $4,071 | $8,636 |
| External Services | $2,420 | $1,359 | $4,700 | $20,085 |
| Facilities Related | $40 | $482 | $694 | $1,730 |
| Other | $113 | $323 | $524 | $1,115 |
| Total R&D Expense | $3,551 | $3,989 | $9,989 | $31,566 |
Marketing and Sales Costs
Selling, general and administrative expenses (SG&A), which encompass marketing and sales costs, were $26.2 million for the three months ended September 30, 2024, down from $28.6 million in the same period of 2023. For the nine months ended September 30, 2024, SG&A expenses amounted to $84.4 million, an increase from $71.9 million in 2023, representing a 17% increase.
The breakdown of SG&A expenses for the three and nine months ended September 30, 2024, compared to 2023, is as follows:
| Expense Type | Three Months Ended September 30, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Nine Months Ended September 30, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) |
|---|---|---|---|---|
| Selling, General and Administrative | $26,219 | $28,636 | $84,364 | $71,913 |
Manufacturing and Supply Chain Costs
Cost of products sold (COGS) for Innoviva was reported at $10.0 million for the three months ended September 30, 2024, a slight decrease from $10.2 million in the same period of 2023. For the nine months ended September 30, 2024, COGS totaled $29.4 million, which is an increase from $27.9 million in 2023, reflecting a 5% increase.
Details of COGS for the three and nine months ended September 30, 2024, compared to 2023, are as follows:
| Cost Type | Three Months Ended September 30, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Nine Months Ended September 30, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) |
|---|---|---|---|---|
| Cost of Products Sold | $9,990 | $10,182 | $29,433 | $27,910 |
Administrative and Operational Overhead
Administrative and operational overhead costs are primarily embedded within the SG&A expenses. The increase in SG&A expenses for the nine months ended September 30, 2024, can be attributed to ongoing efforts to promote marketed products and maintain regulatory compliance.
The total administrative costs, including overhead, as part of SG&A for the nine months ended September 30, 2024, is reflected in the following table:
| Cost Type | Nine Months Ended September 30, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) |
|---|---|---|
| Total Administrative Costs | $84,364 | $71,913 |
Innoviva, Inc. (INVA) - Business Model: Revenue Streams
Royalties from GSK on respiratory product sales
Innoviva, Inc. earns substantial revenue through royalties from GlaxoSmithKline (GSK) on its respiratory products. For the three months ended September 30, 2024, total net royalty revenue amounted to $60.5 million, an increase from $57.0 million in the same quarter of 2023. For the nine months ended September 30, 2024, total net royalty revenue was $179.2 million, compared to $172.7 million for the same period in 2023.
| Product | Q3 2024 Royalties | Q3 2023 Royalties | 9M 2024 Royalties | 9M 2023 Royalties |
|---|---|---|---|---|
| RELVAR®/BREO® ELLIPTA® | $48.2 million | $45.6 million | $154.3 million | $150.9 million |
| ANORO® ELLIPTA® | $12.3 million | $11.4 million | $35.3 million | $32.1 million |
Product sales from GIAPREZA®, XERAVA®, and XACDURO®
Innoviva's net product sales for the three months ended September 30, 2024, were $27.8 million, with contributions from:
- GIAPREZA®: $13.8 million
- XERAVA®: $4.2 million
- XACDURO®: $9.8 million
For the nine months ended September 30, 2024, total net product sales reached $68.6 million, broken down as follows:
- GIAPREZA®: $39.0 million
- XERAVA®: $15.2 million
- XACDURO®: $14.4 million
License revenue from collaboration agreements
Innoviva recognized $4.6 million in license revenue for the third quarter of 2024. This included:
- $8.0 million for the first quarter of 2024 from Zai Lab for regulatory milestones.
- $19.1 million in license revenue for the nine months ended September 30, 2024, compared to $11.0 million for the same period in 2023.
The increase in license revenue reflects successful collaborations and milestone achievements in product development.
Potential future revenues from new product launches and acquisitions
Innoviva's strategic focus includes potential future revenues from new product launches and acquisitions. The company has expanded its portfolio through acquisitions, such as:
- Entasis Therapeutics, which enhances its critical care and infectious disease offerings.
- La Jolla Pharmaceutical Company, contributing additional marketed products.
These acquisitions are expected to drive future revenue growth as new products are launched and gain market acceptance.
Updated on 16 Nov 2024
Resources:
- Innoviva, Inc. (INVA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Innoviva, Inc. (INVA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Innoviva, Inc. (INVA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.